首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1441192

全球抗菌药物敏感性测试市场规模、份额、成长分析（按测试类型、最终用户、产品类型）- 产业预测，2023-2030 年

Global Antimicrobial Susceptibility Testing Market Size, Share, Growth Analysis, By Test type, By End user, By Product type - Industry Forecast 2023-2030

出版日期: 2024年02月22日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球抗菌药物敏感性测试市场规模为36亿美元，将从2023年的37.9亿美元增长到2031年的56亿美元，预测期内（2024-2031年）复合年增长率为5.20%。至8000万美元。

在抗菌药物抗药性的普遍存在以及对有效治疗策略的需求不断增长的推动下，全球抗菌药物敏感性测试 (AST) 市场正在显着增长。 AST 在帮助临床医生选择合适的抗菌疗法、确保最佳治疗结果以及对抗抗药性病原体的增殖方面发挥着至关重要的作用。 AST 的主要目的是提供准确、及时的微生物对各种抗生素敏感性的资讯。 AST 使医疗保健专业人员能够就抗生素选择、剂量和治疗持续时间做出明智的决定，从而有助于有效管理感染疾病。透过识别最有效的抗生素，AST 有助于制定个人化治疗计划，降低治疗失败的风险，并支持抗菌药物管理工作。有几个关键因素推动抗菌药物敏感性测试市场的成长。抗菌素抗药性负担日益加重，导致发病率、死亡率和医疗费用增加，从而推动了对 AST 的需求。此外，感染疾病爆发和医院感染的迅速增加，以及人们对标靶治疗需求的认识不断增强，正在推动市场扩张。 AST 技术、自动化以及分子诊断与 AST 系统的整合的快速采用将进一步刺激市场成长。然而，在资源有限的环境中，先进的 AST 方法的获取有限、先进测试技术的实施成本较高、测试结果解释的复杂性以及测试方法标准化的挑战。传统的 AST 方法可能会阻碍市场成长。抗菌药物敏感性测试市场的主要趋势包括快速、高精度 AST 系统市场的开拓、用于资料分析的人工智慧 (AI) 和机器学习演算法的引入、以及人工智慧 (AI) 和机器学习的引入用于同时检测多种抗菌药物抗药性模式的演算法，其中包括对多重检测的更多关注。市场上还存在着巨大的成长和创新机会，包括对照护现场检测的需求不断增加、在实验室中采用自动化 AST 系统以及在感染疾病管理中更加重视个人化医疗。诊断公司、研究机构和医疗机构之间的合作有望加速AST技术的进步并扩大其市场范围。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东/非洲
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2021年）
主要市场参与者所采取的策略
关键成功策略
近期市集活动
主要企业市场占有率（2021年）

主要企业简介

赛默飞世尔科技公司（美国）
Bio-Rad 实验室公司（美国）
丹纳赫公司（美国）
贝克顿迪金森公司（美国）
生物梅里埃公司（法国）
罗氏诊断（瑞士）
雅培实验室（美国）
布鲁克公司（美国）
默克公司（德国）
安捷伦科技公司（美国）
ConvaTec Group plc（英国）
造父变星（美国）
HiMedia Laboratories Pvt. Ltd.（印度）
Liofilchem srl（义大利）
加速诊断公司（美国）
创意诊断（美国）
Bio-Rad 实验室（美国）
共生（英国）
ELITech集团（法国）
QIAGEN NV（德国）

简介目录

Product Code: SQMIG35B2120

Global Antimicrobial Susceptibility Testing Market size was valued at USD 3.60 Billion in 2022 and is poised to grow from USD 3.79 Billion in 2023 to USD 5.68 Billion by 2031, at a CAGR of 5.20% during the forecast period (2024-2031).

The global Antimicrobial Susceptibility Testing (AST) Market is experiencing notable growth, fueled by the rising prevalence of antimicrobial resistance and the imperative for effective treatment strategies. AST plays a pivotal role in assisting clinicians in choosing appropriate antimicrobial therapies, ensuring optimal treatment outcomes, and addressing the surge of drug-resistant pathogens. Its primary objective is to furnish accurate and timely information on microorganisms' susceptibility to various antibiotics. AST empowers healthcare professionals to make informed decisions regarding antibiotic selection, dosage, and treatment duration, contributing to the proficient management of infectious diseases. By identifying the most effective antibiotics, AST facilitates personalized treatment plans, mitigates the risk of treatment failure, and supports antimicrobial stewardship initiatives. Several key factors are propelling the growth of the antimicrobial susceptibility testing market. The escalating burden of antimicrobial resistance, leading to increased morbidity, mortality, and healthcare costs, propels the demand for AST. Furthermore, the upsurge in infectious disease outbreaks, hospital-acquired infections, and heightened awareness of the necessity for targeted therapies drive market expansion. The introduction of rapid AST methods, automation, and the integration of molecular diagnostics into AST systems further stimulate market growth. Nevertheless, challenges such as limited access to advanced AST methods in resource-constrained settings, high implementation costs for sophisticated testing technologies, the intricacy of interpreting test results, difficulties in standardizing testing methods, and the time-consuming nature of traditional AST methods may impede market growth. Key trends in the antimicrobial susceptibility testing market involve the development of rapid and precise AST systems, the incorporation of artificial intelligence (AI) and machine learning algorithms for data analysis, and an increased focus on multiplex testing to detect multiple drug resistance patterns simultaneously. The market also presents substantial opportunities for growth and innovation, including the rising demand for point-of-care testing, the adoption of automated AST systems in laboratories, and the growing emphasis on personalized medicine in infectious disease management. Collaborations between diagnostic companies, research institutions, and healthcare organizations are anticipated to drive advancements in AST technologies and expand market reach.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antimicrobial Susceptibility Testing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antimicrobial Susceptibility Testing Market Segmental Analysis

Global Antimicrobial Susceptibility Testing Market is segmented on the basis of test type, end user, product type, and region. By test type, the market is segmented into phenotypic testing, genotypic testing, and rapid testing. By end user, the market is segmented into hospitals and diagnostic laboratories, research and academic institutes, and pharmaceutical and biotechnology companies. By product type, the market is segmented into Instruments, reagents and kits, and software and services. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Antimicrobial Susceptibility Testing Market

The surge in antimicrobial resistance stands out as a major catalyst for the Antimicrobial Susceptibility Testing (AST) market. The advent of drug-resistant pathogens poses a grave and widespread threat to public health. A noteworthy example is the escalating prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infections, underscoring the critical necessity for precise AST. This need arises to guide clinicians in making informed decisions regarding the selection of suitable antibiotics for effective treatment.

Restraints in the Global Antimicrobial Susceptibility Testing Market

Limited access to advanced Antimicrobial Susceptibility Testing (AST) technologies in resource-constrained settings poses a hindrance to market growth. For instance, low-income countries may encounter difficulties in adopting automated AST systems due to their elevated costs and the requirement for adequately trained personnel.

Market Trends of the Global Antimicrobial Susceptibility Testing Market

The incorporation of artificial intelligence (AI) and machine learning algorithms for analyzing Antimicrobial Susceptibility Testing (AST) data is an expanding trend. These technologies play a crucial role in deciphering intricate datasets, enhancing the precision, and expediting the interpretation of AST results. An illustrative instance is the AI-powered platform DeepAMR, which utilizes machine learning to forecast bacterial susceptibility to antibiotics by leveraging genomic data.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Antimicrobial Susceptibility Testing Market by Test type

Market Overview
Phenotypic testing
genotypic testing
and rapid testing

Global Antimicrobial Susceptibility Testing Market by End user

Market Overview
Hospitals and diagnostic laboratories
research and academic institutes
and pharmaceutical and biotechnology companies

Global Antimicrobial Susceptibility Testing Market by Product type

Market Overview
Instruments
reagents and kits
and software and services

Global Antimicrobial Susceptibility Testing Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bioMerieux SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Diagnostics (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bruker Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ConvaTec Group plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cepheid (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
HiMedia Laboratories Pvt. Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Liofilchem s.r.l. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Accelerate Diagnostics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Creative Diagnostics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Synbiosis (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ELITechGroup (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments